The clinical progress of Nutlins and idasanutlin validates the p53/MDM2 pathway as a druggable target in oncology [82], underlining a potential niche for HF especially in p53 wild-type, MDM2-amplified cancers. This evidence concerns the gene TP53 and cancer.